Wow_老虎社区_美港股上老虎

Jamesohl
2021-03-29

Wow

Taiwan says no progress in BioNTech vaccine talks<blockquote>台湾称BioNTech疫苗谈判没有进展</blockquote>

TAIPEI, March 29 (Reuters) - There has been no progress on talks to seal a deal with Germany's BioNT

Taiwan says no progress in BioNTech vaccine talks<blockquote>台湾称BioNTech疫苗谈判没有进展</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":352719738,"tweetId":"352719738","gmtCreate":1617003885724,"gmtModify":1634523196747,"author":{"id":3574700658662797,"idStr":"3574700658662797","authorId":3574700658662797,"authorIdStr":"3574700658662797","name":"Jamesohl","avatar":"https://static.tigerbbs.com/707adfde39b1d8b9102a0329a03899b2","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Wow</body></html>","htmlText":"<html><head></head><body>Wow</body></html>","text":"Wow","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/352719738","repostId":2123235334,"repostType":2,"repost":{"id":"2123235334","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1616999721,"share":"https://www.laohu8.com/m/news/2123235334?lang=zh_CN&edition=full","pubTime":"2021-03-29 14:35","market":"us","language":"en","title":"Taiwan says no progress in BioNTech vaccine talks<blockquote>台湾称BioNTech疫苗谈判没有进展</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2123235334","media":"Reuters","summary":"TAIPEI, March 29 (Reuters) - There has been no progress on talks to seal a deal with Germany's BioNT","content":"<html><body>TAIPEI, March 29 (Reuters) - There has been no progress on talks to seal a deal with Germany's <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> for its COVID-19 vaccine though talks are continuing, Taiwanese Health Minister Chen Shih-chung said on Monday.<blockquote><html><body>路透台北3月29日-与德国达成协议的谈判尚未取得进展<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>台湾卫生部长陈时中周一表示，尽管有关COVID-19疫苗的谈判仍在继续。</body></html></blockquote> Taiwan complained last month that the firm had pulled out of a deal to sell it 5 million doses at the last minute, possibly due to Chinese pressure. BioNTech responded by saying it did plan on providing the vaccine. <blockquote>台湾上个月抱怨说，该公司在最后一刻退出了向其出售500万剂疫苗的协议，可能是由于中国的压力。BioNTech回应称，它确实计划提供疫苗。</blockquote> Speaking at parliament, Chen was downbeat on the chances for finalising the agreement.<blockquote>陈在议会发表讲话时，对最终达成协议的机会感到悲观。</blockquote> \"At present there has been no further progress, and the opportunity for both to complete the contract is getting less and less,\" he added.<blockquote>“目前没有进一步的进展，双方完成合同的机会越来越少，”他补充道。</blockquote> Taiwan has a contract for five million of Moderna Inc's<blockquote>台湾与Moderna Inc签订了500万辆汽车的合同</blockquote> COVID-19 shot, a messenger RNA vaccine that relies on similar technology as that used by the Pfizer-BioNTech <a href=\"https://laohu8.com/S/AONE\">one</a>. <blockquote>COVID-19 shot，一种信使RNA疫苗，依赖于与辉瑞-BioNTech使用的类似技术<a href=\"https://laohu8.com/S/AONE\">一</a>.</blockquote> Chen said that with the Moderna ones coming, as well as domestically made vaccines in development, there was less urgency to obtain the BioNTech <a href=\"https://laohu8.com/S/AONE.U\">one</a>, though Taiwan would still like them if possible.<blockquote>陈表示，随着Moderna疫苗的推出以及国产疫苗的开发，获得BioNTech的紧迫性降低了<a href=\"https://laohu8.com/S/AONE.U\">一</a>尽管如果可能的话，台湾仍然会喜欢它们。</blockquote> \"We are still in communication with them,\" he added. <blockquote>“我们仍在与他们沟通，”他补充道。</blockquote> BioNTech did not immediately respond to a request for comment. <blockquote>BioNTech没有立即回应置评请求。</blockquote> BioNTech signed a deal with Chinese firm Shanghai Fosun Pharmaceutical Group Co Ltd to exclusively develop and commercialise COVID-19 vaccine products developed using BioNTech's mRNA technology in mainland China, Hong Kong, Macau and Taiwan. <blockquote>BioNTech与中国公司上海复星医药集团有限公司签署协议，在中国大陆、香港、澳门和台湾独家开发和商业化使用BioNTech mRNA技术开发的COVID-19疫苗产品。</blockquote> In return it agreed to pay up to $85 million in licensing fees and invest $50 million for a stake in the German firm.<blockquote>作为回报，它同意支付高达8500万美元的许可费，并投资5000万美元购买这家德国公司的股份。</blockquote> BioNTech's development and distribution partner for the rest of the world is U.S. firm Pfizer Inc .<blockquote>BioNTech在世界其他地区的开发和分销合作伙伴是美国辉瑞公司。</blockquote> Taiwan began its vaccination programme this month with AstraZeneca shots. <blockquote>台湾本月开始了阿斯利康疫苗接种计划。</blockquote> There are only 34 active cases being treated in hospital in Taiwan.<blockquote>台湾只有34例活跃病例正在医院接受治疗。</blockquote> (Reporting by Ben Blanchard; Editing by Stephen Coates)<blockquote>（本·布兰查德报道；斯蒂芬·科茨编辑）</blockquote>((ben.blanchard@thomsonreuters.com;))<blockquote>（（ben.blanchard@thomsonreuters.com；））</blockquote></body></html><blockquote></blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Taiwan says no progress in BioNTech vaccine talks<blockquote>台湾称BioNTech疫苗谈判没有进展</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTaiwan says no progress in BioNTech vaccine talks<blockquote>台湾称BioNTech疫苗谈判没有进展</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nReuters \n2021-03-29 14:35\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body>TAIPEI, March 29 (Reuters) - There has been no progress on talks to seal a deal with Germany's <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> for its COVID-19 vaccine though talks are continuing, Taiwanese Health Minister Chen Shih-chung said on Monday.<blockquote><html><body>路透台北3月29日-与德国达成协议的谈判尚未取得进展<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>台湾卫生部长陈时中周一表示，尽管有关COVID-19疫苗的谈判仍在继续。</body></html></blockquote> Taiwan complained last month that the firm had pulled out of a deal to sell it 5 million doses at the last minute, possibly due to Chinese pressure. BioNTech responded by saying it did plan on providing the vaccine. <blockquote>台湾上个月抱怨说，该公司在最后一刻退出了向其出售500万剂疫苗的协议，可能是由于中国的压力。BioNTech回应称，它确实计划提供疫苗。</blockquote> Speaking at parliament, Chen was downbeat on the chances for finalising the agreement.<blockquote>陈在议会发表讲话时，对最终达成协议的机会感到悲观。</blockquote> \"At present there has been no further progress, and the opportunity for both to complete the contract is getting less and less,\" he added.<blockquote>“目前没有进一步的进展，双方完成合同的机会越来越少，”他补充道。</blockquote> Taiwan has a contract for five million of Moderna Inc's<blockquote>台湾与Moderna Inc签订了500万辆汽车的合同</blockquote> COVID-19 shot, a messenger RNA vaccine that relies on similar technology as that used by the Pfizer-BioNTech <a href=\"https://laohu8.com/S/AONE\">one</a>. <blockquote>COVID-19 shot，一种信使RNA疫苗，依赖于与辉瑞-BioNTech使用的类似技术<a href=\"https://laohu8.com/S/AONE\">一</a>.</blockquote> Chen said that with the Moderna ones coming, as well as domestically made vaccines in development, there was less urgency to obtain the BioNTech <a href=\"https://laohu8.com/S/AONE.U\">one</a>, though Taiwan would still like them if possible.<blockquote>陈表示，随着Moderna疫苗的推出以及国产疫苗的开发，获得BioNTech的紧迫性降低了<a href=\"https://laohu8.com/S/AONE.U\">一</a>尽管如果可能的话，台湾仍然会喜欢它们。</blockquote> \"We are still in communication with them,\" he added. <blockquote>“我们仍在与他们沟通，”他补充道。</blockquote> BioNTech did not immediately respond to a request for comment. <blockquote>BioNTech没有立即回应置评请求。</blockquote> BioNTech signed a deal with Chinese firm Shanghai Fosun Pharmaceutical Group Co Ltd to exclusively develop and commercialise COVID-19 vaccine products developed using BioNTech's mRNA technology in mainland China, Hong Kong, Macau and Taiwan. <blockquote>BioNTech与中国公司上海复星医药集团有限公司签署协议，在中国大陆、香港、澳门和台湾独家开发和商业化使用BioNTech mRNA技术开发的COVID-19疫苗产品。</blockquote> In return it agreed to pay up to $85 million in licensing fees and invest $50 million for a stake in the German firm.<blockquote>作为回报，它同意支付高达8500万美元的许可费，并投资5000万美元购买这家德国公司的股份。</blockquote> BioNTech's development and distribution partner for the rest of the world is U.S. firm Pfizer Inc .<blockquote>BioNTech在世界其他地区的开发和分销合作伙伴是美国辉瑞公司。</blockquote> Taiwan began its vaccination programme this month with AstraZeneca shots. <blockquote>台湾本月开始了阿斯利康疫苗接种计划。</blockquote> There are only 34 active cases being treated in hospital in Taiwan.<blockquote>台湾只有34例活跃病例正在医院接受治疗。</blockquote> (Reporting by Ben Blanchard; Editing by Stephen Coates)<blockquote>（本·布兰查德报道；斯蒂芬·科茨编辑）</blockquote>((ben.blanchard@thomsonreuters.com;))<blockquote>（（ben.blanchard@thomsonreuters.com；））</blockquote></body></html><blockquote></blockquote>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2123235334","content_text":"TAIPEI, March 29 (Reuters) - There has been no progress on talks to seal a deal with Germany's BioNTech SE for its COVID-19 vaccine though talks are continuing, Taiwanese Health Minister Chen Shih-chung said on Monday. Taiwan complained last month that the firm had pulled out of a deal to sell it 5 million doses at the last minute, possibly due to Chinese pressure. BioNTech responded by saying it did plan on providing the vaccine. Speaking at parliament, Chen was downbeat on the chances for finalising the agreement. \"At present there has been no further progress, and the opportunity for both to complete the contract is getting less and less,\" he added. Taiwan has a contract for five million of Moderna Inc's COVID-19 shot, a messenger RNA vaccine that relies on similar technology as that used by the Pfizer-BioNTech one. Chen said that with the Moderna ones coming, as well as domestically made vaccines in development, there was less urgency to obtain the BioNTech one, though Taiwan would still like them if possible. \"We are still in communication with them,\" he added. BioNTech did not immediately respond to a request for comment. BioNTech signed a deal with Chinese firm Shanghai Fosun Pharmaceutical Group Co Ltd to exclusively develop and commercialise COVID-19 vaccine products developed using BioNTech's mRNA technology in mainland China, Hong Kong, Macau and Taiwan. In return it agreed to pay up to $85 million in licensing fees and invest $50 million for a stake in the German firm. BioNTech's development and distribution partner for the rest of the world is U.S. firm Pfizer Inc . Taiwan began its vaccination programme this month with AstraZeneca shots. There are only 34 active cases being treated in hospital in Taiwan. (Reporting by Ben Blanchard; Editing by Stephen Coates)((ben.blanchard@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1557,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}